AMERICAN RADIOSURGERY

PRESS RELEASE

For Immediate Release:

Contact:
Katie Clark
American Radiosurgery
Ph: (858) 451-6173
Fax: (858) 487-0662
info@americanradiosurgery.net
www.americanradiosurgery.net

Explorer4D™ Treatment Planning System Receives FDA Approval

San Diego, CA, January 19, 2010 - American Radiosurgery, Inc., announced today that its 510(k) submission for the Explorer4D™ Treatment Planning System (TPS) has received FDA clearance. The Explorer4D Treatment Planning System is a sophisticated software package that optimizes dose planning for use with the Rotating Gamma Systems®, a line of radiosurgery devices used in the non-invasive treatment of brain tumors and brain disorders.

Mr. John Clark, Chairman and CEO of American Radiosurgery commented on the notification of FDA clearance, "The inclusion of Explorer4D on the treatment planning software market raises the bar for dose planning in radiosurgery. This product gives our neurosurgeons and radiation oncologists unparalleled access to targets and helps assure maximum radiation safety."

The Explorer4D TPS differs from comparable products in that it runs on open-source OsiriX™ medical image viewing software. The software provides real time dose calculations and updates as well as automatic skin detection and easy monitoring of point dose distribution.

Mr. Clark added, "The Explorer4D stands alone in its ability to facilitate intensity modulated radiosurgery (IMRS). This means we can turn radioactive sources on and off during patient treatments, eliminating the need to manually plug or shut collimators. Explorer4D allows us to expedite patient treatment time with minimal risk of radiation to surrounding healthy tissue."

American Radiosurgery, Inc., is based in San Diego, California and is a neurosurgical/radiosurgical device company providing advanced technology for the non-invasive treatment of brain tumors and other brain disease entities.

###

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.